Reduce slowness stiffness and instability
- Trial ID
- NCT06383247
- Official Title
- A Randomized, Double-blind, Multicenter, Placebo-controlled Trial (PRESS-PD)
- Goal
- Reduce slowness stiffness and instability
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Anhui Medical University
- Study Type
- INTERVENTIONAL
- Enrollment
- 290 participants
- Conditions
- Parkinson Disease, Transcranial Magenetic Stimualtion, Supplementary Motor Area
- Interventions
- transcranial magnetic stimulation
Plain-Language Summary
PRESS-PD is testing whether focused magnetic stimulation of the brain's supplementary motor area can ease core motor problems in Parkinson's, like slowness, stiffness, and unstable motor control. It uses repetitive transcranial magnetic stimulation, a noninvasive device that delivers magnetic pulses to change cortical excitability and strengthen motor circuit connections, and because it is not a drug it does not chemically interact with levodopa while participants keep stable medication doses. The trial is enrolling adults 40 and older with idiopathic Parkinson's, MDS-UPDRS part III score of at least 8, Hoehn‑Yahr stage 1 to 4, MMSE ≥22, stable meds for 4 weeks, and no epilepsy, metal implants, deep brain stimulation, major brain injury, or recent trial participation.
Locations
- Cognitive Neuropsychology Lab Anhui Medical University, Hefei, Anhui, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying transcranial magnetic stimulation. PRESS-PD is testing whether focused magnetic stimulation of the brain's supplementary motor area can ease core motor problems in Parkinson's, like slowness, stiffness, and unstable motor control. It uses repetitive transcranial magnetic stimulation, a noninvasive device that delivers magnetic pulses to change cortical excitability and strengthen motor circuit connections, and because it is not a drug it does not chemically interact with levodopa while participants keep stable medication doses. The trial is enrolling adults 40 and older with idiopathic Parkinson's, MDS-UPDRS part III score of at least 8, Hoehn‑Yahr stage 1 to 4, MMSE ≥22, stable meds for 4 weeks, and no epilepsy, metal implants, deep brain stimulation, major brain injury, or recent trial participation.
- Who can participate?
- Participants must be at least 40 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 1 month.